News18 News

Ozempic Comes To India At Rs 2,200 Weekly Dose, Novo Nordisk Cautions Against Unsupervised Use

Ozempic has been approved for type-2 diabetes, while Novo Nordisks other global blockbuster Wegovy is targeted at obesity.